eCoin Peripheral Neurostimulator
BOSTON SCIENTIFIC CORPORATION · Decision date Mar 1, 2022
What did the FDA approve?
The FDA record for P200036 shows an original PMA approval, dated 2022-03-01, for the eCoin Peripheral Neurostimulator from Boston Scientific Corporation. The product code is QPT, categorized as an implantable electrical tibial stimulator for urinary incontinence, with gastroenterology and urology listed as specialties. No supplement type or supplement reason appears in the record, so the scope described is the original approval rather than a later change to an existing PMA.
The supplied statement describes the device as intended to treat urgency urinary incontinence in patients who are intolerant to, or have an inadequate response to, other more conservative treatments, or who have undergone a successful trial of percutaneous tibial nerve stimulation. That wording is the statement's reported purpose; the record contains no independent safety or clinical effectiveness data and no details on the trial referenced. Specifics such as device design, stimulation parameters and post-approval requirements are absent.
FDA approval order statement
Approval of the eCoin Peripheral Neurostimulator. The device is intended to be used to treat urgency urinary incontinence in patients intolerant to or having an inadequate response to other more conservative treatments or who have undergone a successful trial of percutaneous tibial nerve stimulation.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Mar 1, 2022
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P200036
- Regulatory pathway
- Premarket approval application
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- QPT
- Decision code
- APPR
- Decision date
- Mar 1, 2022
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, tibial, electrical, implantable, for urinary incontinence.
- Applicant
- Boston Scientific Corporation
- Product code
- QPT
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P200036 received
Application receipt date recorded by FDA.
P200036 · FDA decision
APPR
P200036/S009 · Related supplement
eCoin Tibial Nerve Stimulator System
P200036/S010 · Related supplement
eCoin Peripheral Neurostimulator
P200036/S011 · Related supplement
eCoin Peripheral Neurostimulator
P200036/S012 · Related supplement
eCoin Peripheral Neurostimulator
Timeline entries are records held by MedtechLedger for P200036. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200036
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
eCoin Tibial Nerve Stimulator SystemP200036/S009 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 2, 2025 | FDA |
eCoin Peripheral NeurostimulatorP200036/S010 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Mar 3, 2026 | FDA |
eCoin Peripheral NeurostimulatorP200036/S011 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Jul 20, 2026 | FDA |
eCoin Peripheral NeurostimulatorP200036/S012 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Sep 9, 2026 | FDA |
Explore the linked device profile
Other records with product code QPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AltavivaP240011/S016 | Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA |
AltavivaP240011/S015 | Medtronic Neuromodulation | PMA supplement | Aug 14, 2026 | FDA |
AltavivaP240011/S010 | Medtronic Neuromodulation | PMA supplement | Jul 13, 2026 | FDA |
AltavivaP240011/S014 | Medtronic Neuromodulation | PMA supplement | Jun 16, 2026 | FDA |
AltavivaP240011/S013 | Medtronic Neuromodulation | PMA supplement | May 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 100 Boston Scientific Way, Marlborough, MA, 01752
Sources and methodology
- Original FDA record: P200036
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




